Skip to content

Intraperitoneal Carbon Dioxide Concentration Measurement During Standard Laparoscopy With a New Airseal Access Port

SurgiQuest AirSeal CO2 Gas Quality

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01017887
Enrollment
0
Registered
2009-11-23
Start date
2011-10-31
Completion date
2013-10-31
Last updated
2013-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Carbon Dioxide Measurement

Keywords

laparoscopy, airseal, carbon dioxide, insufflation, pneumoperitoneum

Brief summary

The new AirSeal access port for laparoscopic surgery does not use a mechanical valve on the port to maintain gas in the peritoneal cavity. It uses an invisible barrier created by high flow gas jets within the port. The percentage of carbon dioxide, the standard gas used for laparoscopy, during laparoscopic surgery has not been previously measured, but is probably high. The investigators aim to measure the percentage of intraperitoneal carbon dioxide with standard ports and the AirSeal port during a variety of conditions during laparoscopic procedures including suturing and suctioning. The study period will commence at the start of the operation, and be completed upon discharge from the hospital or postoperative day 5, whichever is shorter. All devices are approved for use in humans by the FDA, and are being used for their intended purpose.

Detailed description

The SurgiQuest AirSeal system is approved by the Food and Drug Administration (FDA) as access port for laparoscopic surgery that utilizes an invisible air curtain rather than a mechanical barrier to maintain pneumoperitoneum. In addition to the cannula, there is special filtration tubing and an air pump that act in concert with an existing CO2 insufflator. The system has been approved for use and purchase at Baystate Medical Center by the value analysis committee. Despite FDA approval and extensive laboratory testing, there is still no human data regarding intraperitoneal CO2 levels under a variety of conditions one would normally experience during a laparoscopic operation. The specific aim of this study is to measure these levels during laparoscopic cases in humans. We hypothesize that there will be no more than minimal alteration of intraperitoneal CO2 levels when using the AirSeal system when compared to the standard laparoscopic system. The follow-up to this is examining evidence of extraperitoneal gas extravasation. This will occur as part of routine post-operative care, but we will be collecting data, that will be de-identified in the post-operative period.

Interventions

DEVICEAirseal access port for laparoscopic surgery

The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.

DEVICEStandard Laparoscopy ports

Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.

Sponsors

Baystate Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients undergoing a laparoscopic operation

Exclusion criteria

* pregnancy

Design outcomes

Primary

MeasureTime frameDescription
percent of intraperitoneal carbon dioxide during surgeryintraoperative - starts at beginning of the operation and ends at the completion of the operationintraperitoneal carbon dioxide measurements intraoperatively

Secondary

MeasureTime frame
subcutaneous emphysemaduring the patients hospital stay, or the first 5 days postoperatively.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026